Does New York Medicaid Cover Wegovy or Zepbound? NYRx's BMI 40 and Lifetime Limits

Not for weight loss. NYRx, New York’s Medicaid drug program, excludes GLP-1s for weight loss, but as of November 2026 it covers Wegovy for established cardiovascular disease and Zepbound for moderate to severe sleep apnea.^[1] Both routes require prior authorization and a BMI of at least 40, and both stop at two treatment attempts in a lifetime.^[4][5][6]

Does NYRx cover Wegovy or Zepbound for weight loss?

No. The program’s overview says bluntly that Medicaid in New York has never covered weight loss as a use.^[2] States may leave weight-loss agents out under federal law, and New York’s regulation refuses payment for a drug whose sole clinical use is weight reduction.^[3][11] The NYRx overview names Ozempic, Wegovy and Mounjaro as excluded for that purpose.^[2] A diagnosis of obesity alone will not open either route.

New York moved its pharmacy benefit from managed care to NYRx, so these rules, more than a health plan’s formulary, are the place to start.^[9] Check with the program if your coverage is unusual, such as a plan type outside regular Medicaid.

What does NYRx require for Wegovy and Zepbound?

The forms also ask about diabetes and bar a second GLP-1 at the same time.^[7][8] Each form gives a space for a clinical reason when a requirement cannot be met, such as why CPAP is not appropriate. NYRx says it answers faxed requests within 24 hours.^[7][8]

Why is the BMI 40 line so important?

It sits far above the label. Wegovy’s heart use takes in adults with cardiovascular disease who carry excess weight of either grade, and SELECT, the trial behind it, enrolled people from a BMI of 27.^[13][15] Zepbound’s sleep apnea use covers adults with obesity, which generally begins at a BMI of 30.^[14] So someone with a prior heart attack and a BMI of 38 meets the label and misses the New York test. For contrast, Texas Medicaid’s Wegovy route accepts an overweight diagnosis.

One wording point matters if your BMI is right at 40. The Wegovy overview dated July 2026 says above 40, while the drug list revised October 22, 2026 says 40 or more.^[4][6] Ask the NYRx clinical call center which applies. The form records BMI at the start of therapy, so someone moving from another insurer can report that starting figure.^[7][8]

What does two treatment attempts per lifetime mean?

NYRx counts how many times you have tried the drug for that use, and a third attempt calls for a clinical reason on the form.^[4][5][7][8] The documents do not define exactly what ends an attempt. The renewal questions treat adherence as consistent use with no lapses, including under a previous insurer, so a long gap is the event to discuss with your prescriber before it happens.^[7][8] If you need to pause for a reason such as surgery or a side effect, ask how NYRx would count it, and have your prescriber write down the reason at the time.

Does NYRx cover Wegovy for MASH?

We found no route. The September 21, 2026 overview lists three covered uses (type 2 diabetes, heart events and sleep apnea), and the drug list row for Wegovy names cardiovascular disease only.^[1][6] Wegovy’s label does include noncirrhotic MASH with moderate to advanced fibrosis, so a prescriber can raise it with the clinical call center.^[13] Our guide to GLP-1s for fatty liver covers the trial evidence.

Does New York Medicaid cover Ozempic, Mounjaro and other diabetes GLP-1s?

Yes, for type 2 diabetes. On the October 22, 2026 list, exenatide, the Ozempic pen, Trulicity and Victoza are preferred. Generic liraglutide, Mounjaro, Ozempic tablets, Rybelsus and the insulin combinations Soliqua and Xultophy are non-preferred.^[6] Preferred drugs can pay at the pharmacy without a prior authorization when the claim history already shows a qualifying diagnosis, so your prescriber should send diagnosis codes with claims.^[2] Non-preferred drugs need one.^[2] NYRx will also reject a second GLP-1 or a second strength until 25% or less of the current fill remains, which can catch people moving up a dose early.^[2]

What about members under 21?

The NYRx overviews set no separate pediatric route. Federal child-health rules require Medicaid to provide necessary treatment to people under 21 whether or not the state plan covers it.^[12] Wegovy’s label reaches obesity from age 12.^[13] We found no New York document applying that duty to GLP-1s, so a family facing a refusal should ask for a medical necessity review under EPSDT by name and be ready to request a hearing.

How do you appeal an NYRx denial?

Start with the prior authorization itself, since a missing document can be fixed by resubmitting. If the request is still refused, New York’s fair hearing rule gives 60 days after the agency’s determination, action or failure to act.^[10] Your notice controls, so follow its date and instructions if they differ. An appeal has the most to work with when it argues your facts fit a covered use: a sleep study result, six months of heart medicines or a documented reason you cannot use CPAP. A case built on the BMI line or on weight loss itself has much less, and the forms warn that false statements carry False Claims Act penalties.^[8] Our guide to prior authorization and appeals shows what to include, and the Medicaid Zepbound explainer covers the federal hearing rights.

What can you do if you don't qualify?

Older weight-loss pills are unlikely to help here. New York’s regulation pays for amphetamine-like substances only for conditions other than obesity or weight reduction, which is the group phentermine belongs to, and it appears nowhere on the list we searched.^[3][6] Our phentermine and GLP-1 comparison is useful if you are weighing it at your own cost.

Lilly’s savings card for insured patients excludes Medicaid enrollees.^[16] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up for Lilly’s Zepbound KwikPen or vial, when each refill comes within 45 days.^[16][17] Read each offer’s terms for government-program limits. Our list of GLP-1 prices without insurance compares the routes.